Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 2/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23577145 | 0.83 | DUT (0.32) | DUT | |
| SCHEMBL2262948 | 0.78 | DUT (0.42) | DUTGRM2NPC1RAB9A | |
| SCHEMBL23546502 | 0.75 | KMO (0.41) | DUTNPC1RAB9AKMT2A | |
| SCHEMBL18311614 | 0.74 | GRM2 (0.56) | GRM2KDM4E | |
| SCHEMBL2263579 | 0.73 | DUT (0.52) | DUTNPC1RAB9AKMT2A | |
| SCHEMBL29561346 | 0.73 | TDO2 (0.40) | GRM2KDM4ENPC1RAB9AKMT2A | |
| SCHEMBL20608120 | 0.73 | TDO2 (0.40) | GRM2KDM4ENPC1RAB9AKMT2A | |
| SCHEMBL18070761 | 0.73 | GRM2 (0.51) | GRM2KDM4ENPC1RAB9A | |
| SCHEMBL309493 | 0.72 | GRM2 (0.51) | GRM2 | |
| SCHEMBL2145297 | 0.72 | GLS (0.56) | DUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303517-A1 | DIHYDROCYCLOPENTA-ISOQUINOLINE-SULFONAMIDE DERIVATIVES COMPOUNDS | UCB BIOPHARMA SRL (SOCIETE A RESPONSABILITE LIMITEE) (GB) | 2023-09-28 | — | — | US | disclosed |
| US-20230303517-A1 | DIHYDROCYCLOPENTA-ISOQUINOLINE-SULFONAMIDE DERIVATIVES COMPOUNDS | UCB BIOPHARMA SRL (SOCIETE A RESPONSABILITE LIMITEE) (GB) | 2023-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303517-A1 | DIHYDROCYCLOPENTA-ISOQUINOLINE-SULFONAMIDE DERIVATIVES COMPOUNDS | FCER2, FCGR1A, FCGR2A | DUT 2266/4885GRM2 1417/4885KDM4E 1848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.